A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

NCT Number	NCT06195228
Lead Sponsor	Fudan University Collaborators: Peking Union Medical College Hospital, Shanxi Province Cancer Hospital, Henan Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhejiang Cancer Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Ruijin Hospital, Fujian Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shanghai 6th People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 10th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Changhai Hospital, Tianjin Medical University Cancer Institute and Hospital, Jiangsu Cancer Institute & Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hunan Provincial People's Hospital, Dalian Friendship Hospital Affiliated to Dalian Medical University, The Third Affiliated Hospital of Soochow University, Sun Yat-sen University, Liaoning Cancer Hospital & Institute, Sir Run Run Shaw Hospital
Conditions	Advanced Thyroid Cancer Patients Who Received Target Therapy
Enrollment	800 participants
Start Date	2020-01-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-14